Singular Genomics Reports Recent Highlights and Third Quarter 2023 Financial Results

$OMIC
Biotechnology: Laboratory Analytical Instruments
Industrials
Get the next $OMIC alert in real time by email

SAN DIEGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the third quarter ended September 30, 2023.

"We shipped five G4 systems in the third quarter, our highest quarterly total yet, launched Max Read flow cell kits for single cell sequencing, and saw our largest number of quarterly consumable kit orders," said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics. "In the near term, we will be building our installed base more aggressively and prioritizing fewer yet higher impact products on our product roadmap. We have also cut costs to extend runway, providing time to build our installed base, get high-impact products to market, and scale revenue."

Third Quarter and Recent Highlights

  • Generated revenue of $0.5 million in the third quarter of 2023.
  • Shipped five G4 systems in the third quarter of 2023, increasing the total number of commercial systems shipped to 16 as of the end of the third quarter of 2023.
  • Converted the majority of the installed base to F3 flow cells, allowing users to get up to 450 million reads per flow cell, or 1.8 billion reads per run, for some of the most widely run applications.
  • Completed the early access program and commenced the broad commercial launch of Max Read flow cell kits for single cell sequencing, enabling 800 million reads per flow cell, or 3.2 billion reads per run.
  • Implemented cost-cutting measures, including a workforce reduction of approximately 10%, to reduce operating expenses and extend cash runway into the first quarter of 2026.



Third Quarter 2023 Financial Results

Revenue for the third quarter of 2023 was $0.5 million, driven primarily by recognition of sales on one instrument placement. The company expects revenue from the remaining four instrument shipments to be recognized over time as customers purchase consumables for these instruments.

Operating expenses for the third quarter of 2023 totaled $24.5 million, compared to $24.7 million for the third quarter of 2022. Operating expenses included non-cash stock-based compensation of $2.8 million for the third quarter of 2023 and $3.4 million for the third quarter of 2022. The year over year decrease in total operating expenses was driven primarily by a decrease in research and development materials and other general lab supply costs as the company transitioned from development to commercialization of the G4.

Net loss for the third quarter of 2023 was $22.4 million, or a loss of $0.31 per common share, compared to $23.8 million, or a loss of $0.33 per common share, for the third quarter of 2022.

Cash, cash equivalents and short-term investments, excluding restricted cash, totaled $190.7 million as of September 30, 2023.

Webcast and Conference Call Details

Singular Genomics' management team will host a conference call today, November 14, 2023, beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing 1-888-506-0062 for domestic callers or 1-973-528-0011 for international callers and using conference ID 616134 approximately five minutes prior to the start time. A live and archived webcast of the event will be available at investor.singulargenomics.com, in the Presentations & Events section.

About Singular Genomics Systems, Inc.

Singular Genomics is a life science technology company that develops next-generation sequencing and multiomics technologies. The commercially available G4 Sequencing Platform is a powerful, highly versatile benchtop genomic sequencer designed to produce fast and accurate results. In addition, Singular Genomics commenced development of the PX system, which leverages Singular's proprietary sequencing technology, applying it as an in situ readout to look at RNA and proteins in single cells and tissue. Singular Genomics' mission is to empower researchers and clinicians to advance science and medicine. Visit www.singulargenomics.com for more information.

Forward-Looking Statements

Certain statements contained in this press release, other than historical information, constitute forward-looking statements within the meaning of the federal securities laws. Forward-looking statements include, but are not limited to, statements regarding: (i) our ability to successfully manufacture, commercialize and support the G4 and our flow cell kits in accordance with our timelines, objectives and specifications; (ii) our ability to ship Max Read kits to our broader customer base on our timeline; (iii) our expectations on cash runway, including whether our cost-cutting measures will have any material impact on our operating expenses or cash runway; (iv) our expectations regarding future revenue; and (v) quotes of management. Any such forward-looking statements are based on our management's current expectations and are subject to risks and uncertainties that could cause our actual future results to differ materially from our management's current expectations or those implied by our forward-looking statements. These risks and uncertainties include, but are not limited to, the following: (i) we have incurred significant losses since inception, we expect to incur significant losses in the future and we may not be able to generate sufficient revenue to achieve and maintain profitability; (ii) we have very little history manufacturing and commercializing our products or technology; (iii) the life sciences technology market is highly competitive, and if we fail to compete effectively, our business and operating results will suffer; (iv) if we are sued for infringing, misappropriating or otherwise violating intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our products; (v) if our products fail to achieve early customer and scientific acceptance, we may not be able to achieve broader market acceptance for our products, and our revenues and prospects may be harmed; (vi) we expect to be highly dependent upon revenue generated from the sale of the G4 and future products, and any delay or failure by us to successfully manufacture and commercialize the G4 and future products could have a substantial adverse effect on our business and results of operations; and (vii) recent macroeconomic challenges such as inflation and rising interest rates may materially and adversely impact our business, operations, product manufacturing and commercialization objectives. These and other risk factors that may affect our future results of operations are identified and described in more detail in our most recent filings on Forms 10-K and 10-Q and in other filings that we make with the SEC from time to time, including our Quarterly Report on Form 10-Q for the period ended September 30, 2023, filed with the SEC on November 14, 2023. Accordingly, you should not rely on forward-looking statements as predictions of future events or our future performance. Except as required by law, we undertake no obligation to update publicly or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Investor Contact

Matt Clawson

949-370-8500

ir@singulargenomics.com

Media Contact

Dan Budwick, 1AB

973-271-6085

dan@1abmedia.com



Singular Genomics Systems, Inc.

Statements of Operations

(Unaudited)

(In thousands, except share and per share amounts)
      
 Three Months Ended September 30,  Nine Months Ended September 30, 
 2023  2022  2023  2022 
            
Revenue$462  $-  $1,830  $- 
Cost of revenue 527   -   1,931   - 
Gross margin (65)  -   (101)  - 
Operating expenses:           
Research and development 11,220   12,732   36,074   35,439 
Selling, general and administrative 13,254   11,962   41,345   35,518 
Total operating expenses 24,474   24,694   77,419   70,957 
Loss from operations (24,539)  (24,694)  (77,520)  (70,957)
Other income (expense):           
Interest expense (285)  (211)  (814)  (520)
Interest and other income 2,464   1,115   6,763   1,699 
Total other income 2,179   904   5,949   1,179 
Net loss$(22,360) $(23,790) $(71,571) $(69,778)
Net loss per share:           
Basic and diluted net loss per share$(0.31) $(0.33) $(0.99) $(0.98)
Weighted-average shares used to compute basic and diluted net loss per share 73,178,822   71,216,292   72,541,979   71,001,441 



       
Singular Genomics Systems, Inc.

Balance Sheets

(In thousands, except share and par value amounts)
       
  September 30,  December 31, 
  2023  2022 
  (Unaudited)    
Assets      
Current assets:      
Cash and cash equivalents $33,301  $74,266 
Short-term investments  157,416   170,310 
Accounts receivable  399   913 
Inventory  13,420   18,221 
Prepaid expenses and other current assets  6,259   4,722 
Total current assets  210,795   268,432 
Right-of-use lease assets  58,474   45,896 
Property and equipment, net  13,426   10,784 
Restricted cash  1,711   1,711 
Other noncurrent assets  112   1,152 
Total assets $284,518  $327,975 
       
Liabilities and Stockholders' Equity      
Current liabilities:      
Accounts payable $2,432  $3,099 
Accrued expenses  5,063   4,583 
Lease liabilities, current  7,706   6,323 
Other current liabilities  252   113 
Total current liabilities  15,453   14,118 
Lease liabilities, noncurrent  59,124   42,456 
Long-term debt, net of issuance costs  10,175   10,065 
Other noncurrent liabilities  739   1,015 
Total liabilities  85,491   67,654 
Commitments and contingencies      
Stockholders' equity:      
Series A common stock equivalent convertible preferred stock, $0.0001 par value; 7,000 shares authorized, 2,500 shares issued and outstanding at September 30, 2023 and December 31, 2022  -   - 
Common stock, $0.0001 par value; 400,000,000 shares authorized, 73,343,510 and 71,854,688 shares outstanding at September 30, 2023 and December 31, 2022, respectively  7   7 
Additional paid-in capital  513,580   503,926 
Accumulated other comprehensive loss  (214)  (837)
Accumulated deficit  (314,346)  (242,775)
Total stockholders' equity  199,027   260,321 
Total liabilities and stockholders' equity $284,518  $327,975 



Primary Logo

Get the next $OMIC alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$OMIC

DatePrice TargetRatingAnalyst
8/17/2022$10.00 → $4.50Buy → Neutral
UBS
8/10/2022$3.50Buy → Neutral
Goldman
8/10/2022$3.00Buy → Underperform
BofA Securities
1/7/2022$21.00Neutral → Buy
BofA Securities
10/15/2021Outperform
Cowen
More analyst ratings

$OMIC
Press Releases

Fastest customizable press release news feed in the world

See more
  • Singular Highlights Key G4Xâ„¢ Launch Milestones and Showcases Groundbreaking 3D Spatial Multiomic Performance at AGBT

    SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc., an innovator in high-throughput spatial multiomics technologies designed to advance precision medicine, today announced key development milestones for its G4Xâ„¢ Spatial Sequencer at the Advances in Genome Biology and Technology (AGBT) conference in Marco Island, Florida. G4X Early Access Program Ongoing and Broader Availability on Track The G4X Early Access Program is currently underway at Beth Israel Deaconess Medical Center and Vanderbilt University Medical Center, providing valuable feedback highlighting the platform's real-world potential. "As the first early access site, we've had the chance to

    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Singular Genomics Announces Closing of Acquisition by Deerfield Management

    SAN DIEGO, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, announced today the closing of its acquisition by an affiliate of Deerfield Management Company, L.P.    On December 23, 2024, Singular Genomics announced that Deerfield had signed a definitive agreement to acquire all of the outstanding shares of Singular Genomics common stock not currently owned by Deerfield for $20.00 per share in cash. Following the satisfaction of customary conditions, including a vote of the holders of Singular Genomics' common stock to approv

    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Singular Genomics Enters into Agreement to be Acquired by Deerfield for $20.00 in Cash per Share

    SAN DIEGO, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC) ("Singular Genomics" or the "Company"), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that it has entered into a definitive merger agreement whereby an affiliate of Deerfield Management Company, L.P. will acquire Singular Genomics in an all-cash transaction for $20.00 per share. The $20.00 per share represents 254% premium to the last closing share price for Singular's common stock prior to the September 12, 2024 public disclosure of Deerfield's initial acquisition proposal. The Singular Genomic

    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$OMIC
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$OMIC
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$OMIC
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$OMIC
SEC Filings

See more

$OMIC
Leadership Updates

Live Leadership Updates

See more
  • Singular Genomics Appoints Genomics Veteran Marcia Eisenberg, Ph.D., to Board of Directors

    SAN DIEGO, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the appointment of Marcia Eisenberg, Ph.D., to the Company's Board of Directors. Dr. Eisenberg currently serves as Senior Vice President and Enterprise Chief Scientific Officer at Labcorp (NYSE:LH) and brings more than 30 years of experience with molecular genetics, DNA testing, biotechnology, and molecular oncology. "Marcia's deep and diverse genomics expertise will be an asset to Singular as we drive our business strategy forward, and we are delighted to w

    $LH
    $OMIC
    Medical Specialities
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Singular Genomics Appoints Sam Ropp, Ph.D., as Chief Commercial Officer

    SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the appointment of Sam Ropp, Ph.D., as Chief Commercial Officer. In this role, Dr. Ropp will oversee the company's commercial function, including commercialization of the G4 Sequencing Platform. He will report to Drew Spaventa, Chief Executive Officer and Founder of Singular Genomics. The company also announced the appointment of Jeff Bullard as Head of Sales for North America. "As an accomplished life science leader, Sam brings the deep knowledge and experi

    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Singular Genomics Appoints Genomics Research Pioneer Elaine R. Mardis, Ph.D., to Board of Directors

    LA JOLLA, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the addition of Elaine R. Mardis, Ph.D., to the Company's Board of Directors. Dr. Mardis is a pioneering researcher internationally recognized in cancer genomics with a focus on the application of genomic technologies to improve the understanding of human disease and the precision of medical diagnosis, prognosis and treatment. "We are thrilled to have Elaine join the Board of Directors. She brings the rare combination of world-class scientific, indust

    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$OMIC
Financials

Live finance-specific insights

See more
  • Singular Genomics Reports Recent Updates and Third Quarter 2024 Financial Results

    SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the third quarter ended September 30, 2024. "In the third quarter, we made significant progress in the development of the G4X spatial sequencer," said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics. "We are encouraged by the interest in the G4X and validation received through the expansion of our Spatial Technology Access Services project funnel, which reinfo

    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Singular Genomics Reports Recent Highlights and Second Quarter 2024 Financial Results

    SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the second quarter ended June 30, 2024. "It was another busy and productive quarter for our team as we progressed development of the G4X Spatial Sequencer while supporting our G4 customers," said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics. "The early interest in our Spatial Technology Access Services is an encouraging sign that the unique capabilities and

    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Singular Genomics to Report Second Quarter 2024 Financial Results on August 13, 2024

    SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the second quarter ended June 30, 2024 after the market close on Tuesday, August 13, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing 1-888-506-0062 for domestic callers or 1-973-528-0011 for international callers and using conference ID 66

    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$OMIC
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more